DURHAM — Chimerix Inc., a biopharmaceutical company, appointed Martha J. Demski as the new chair of its board, and it also appointed three new board members.
The Securities and Exchange Commission filing can be found online.
Demski has over 30 years of experience in the fields of finance and biotechnology. She has served as one of the company’s directors since 2005 and serves as chair of the audit committee. Previously, she served as vice president and chief financial officer of Vical Inc., a biopharmaceutical company. In addition, she has over 13 years of banking experience with Bank of America and U.S Trust.
Demski will succeed Ernest Mario, who is retiring as of the Chimerix 2018 annual meeting in June.
In addition, Edward F Greissing Jr., Robert J. Meyer and Fred Middleton joined the board on March 28.
John Leonard and James Niedel will step down from the Board in June as well.
Greissing will serve on and chair the nominating and governance committee, and Meyer will serve on the compensation committee. Middleton will serve on and chair the audit committee.
“Chimerix has successfully progressed brincidofovir to clinical trials that truly have the potential to change the outcomes for patients with life-threatening illnesses,” said Demski in a statement. “I am confident in the Chimerix team and proud to be working with them and the Board during this pivotal time in the company’s history.”
Chimerix is developing medicines that protect immunocompromised patients from potentially devastating viral infections.
Chimerix is also pursuing new treatments for hepatitis C virus, flu, malaria and other global public health needs.
This story is from the North Carolina Business News Wire, a service of UNC-Chapel Hill’s School of Media and Journalism
